Brokerages Set Versartis, Inc. (VSAR) Price Target at $29.43


Brokerages Set Versartis, Inc. (VSAR) Price Target at $29.43

Jpmorgan Chase holds 0% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 858,141 shares.

Kingdon Capital Management Llc decreased Versartis Inc (VSAR) stake by 68.54% reported in 2017Q2 SEC filing. Neuberger Berman Grp Lc owns 4.80 million shares. Tower Research Capital Llc (Trc), New York-based fund reported 100 shares. Fmr Ltd Liability Company reported 0.01% stake. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company's stock valued at $618,000 after purchasing an additional 1,420 shares in the last quarter.

Two years after Versartis $VSAR got out from under a clinical hold on somavaratan (VRS-317), the biotech says its big Phase III study proved to be a bad flop. State Street Corp stated it has 556,718 shares. Deutsche Bank maintained the stock with "Buy" rating in Thursday, July 21 report.

Since March 24, 2017, it had 0 insider buys, and 4 insider sales for $798,195 activity. Sphera Funds Mgmt Limited stated it has 1.12% in Versartis Inc (NASDAQ:VSAR). 1,421 shares were sold by Brumm Joshua T, worth $22,807 on Tuesday, June 13. Also, SVP Paul Westberg sold 1,316 shares of the firm's stock in a transaction on Wednesday, April 19th. This is 12.36 % from the last close price. Cowen & Co maintained Halliburton Company (NYSE:HAL) on Wednesday, September 9 with "Market Perform" rating. Jefferies maintained the shares of ARAY in report on Wednesday, August 23 with "Buy" rating. Therefore 89% are positive. Versartis has a one year low of $7.05 and a one year high of $24.00.

Versartis has a 52 week low of $2.90 and a 52 week high of $24.00 The company's market cap is now $0. Accuray had 17 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Friday, September 22 with "Buy". Cantor Fitzgerald has "Buy" rating and $3400 target.

On September 22 the company was rated "Neutral" by SunTrust Robinson Humphrey which is down from the previous "Buy" rating.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 27th.

On September 22 the company was downgraded to "Neutral" from " in a report from Barclays.

Versartis, Inc. (NASDAQ:VSAR) was downgraded by equities research analysts at SunTrust Banks, Inc. from a "buy" rating to a "hold" rating in a report released on Friday. The rating was initiated by Northland Capital on Thursday, April 7 with "Outperform". On September 22 Morgan Stanley kept the company rating at "Buy" but moved down the price target to $9.00 from $17.00.

The stock decreased 87.62% or $18.93 on September 22, reaching $2.67. About 229,710 shares traded. While Versartis might be broken after this trial, Ascendis Pharma A/S (NASDAQ: ASND) is capitalizing on the loss. It has outperformed by 86.48% the S&P500.

Among 12 analysts covering Versartis Inc (NASDAQ:VSAR), 7 have Buy rating, 1 Sell and 4 Hold. Analysts forecast EPS of $-0.68, up exactly $0.24 or 26.09 % from 2014's $-0.92 EPS. The potentially company-killing data wiped more than 80% off the biotech's stock price, leaving it looking to the readout from an ongoing trial in Japan for a shot at redemption. It now has negative earnings.

Versartis' somavaratan has failed to match Pfizer's Genotropin in a phase 3 pediatric growth hormone deficiency (pGHD) trial.

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.